Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

• Authors: FUCHS Charles S; TOMÁŠEK Jiří; YONG Cho Jae; DUMITRU Filip; PASSALACQUA Rodolfo; GOSWAMI Chanchal; SAFRAN Howard; DOS SANTOS Lucas Vieira; APRILE Giuseppe; FERRY David R; MELICHAR Bohuslav; TEHFE Mustapha; TOPUZOV Eldar; ZALCBERG John Raymond; CHAU Ian; CAMPBELL William; SIVANANDAN Choondal; PIKIEL Joanna; KOSHIJI Minori; HSU Yanzhi; LIEPA Astra M; GAO Ling; SCHWARTZ Jonathan D; TABERNERO Josep
• Year of publication: 2014
• Type: Article in Periodical
• Magazine / Source: The Lancet
• Field: Oncology and hematology
• Description: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy. Our findings validate VEGFR-2 signalling as an important therapeutic target in advanced gastric cancer.